title: Identification of an inhibitory mechanism of luteolin on the insulin-like growth factor-1 ligand-receptor interaction.
abstract: Using single-molecule force measurement and fluorescence imaging, we have demonstrated that luteolin has an inhibitory effect on IGF-1 ligand-receptor binding, the initial step in IGF-1 signaling. This inhibition mechanism, which was confirmed by flow cytometry and molecular docking, could play a role in cancer therapy.
authors: Nanomedicine, The Methodist Hospital Research Institute, 6670 Bertner Ave, Houston, TX 77030, USA. yyang@tmhs.org
authors: Yong
authors: Y
authors: Yang
authors: Jianliang
authors: J
authors: Shen
authors: Xujiang
authors: X
authors: Yu
authors: Guoting
authors: G
authors: Qin
authors: Mingzhen
authors: M
authors: Zhang
authors: Haifa
authors: H
authors: Shen
authors: Zongwan
authors: Z
authors: Mao
authors: Mauro
authors: M
authors: Ferrari
mesh_terms: D045744:Cell Line, Tumor; D006801:Humans; D008024:Ligands; D047311:Luteolin / Q000494:pharmacology*; D018625:Microscopy, Atomic Force; D062105:Molecular Docking Simulation; D061848:Optical Imaging; D011485:Protein Binding / Q000187:drug effects; D017526:Receptor, IGF Type 1 / Q000037:antagonists & inhibitors* / Q000378:metabolism
chemical_list: D008024:Ligands; D017526:Receptor, IGF Type 1; D047311:Luteolin
references: Breast Cancer Res Treat. 1994;32(1):85-95
references: 7529598
references: Cell Mol Life Sci. 2005 Feb;62(3):320-43
references: 15723168
references: FASEB J. 2011 Jul;25(7):2201-10
references: 21402719
references: Exp Gerontol. 2003 Oct;38(10):1041-9
references: 14580857
references: Nature. 2006 Sep 14;443(7108):218-21
references: 16957736
references: J Biol Chem. 2003 May 2;278(18):15991-7
references: 12604614
references: Clin Cancer Res. 2008 Oct 15;14(20):6364-70
references: 18927274
references: Proc Natl Acad Sci U S A. 2003 Feb 18;100(4):1603-8
references: 12582206
references: Nat Nanotechnol. 2008 May;3(5):261-9
references: 18654521
references: Cancer Res. 2003 Oct 1;63(19):6432-41
references: 14559833
references: Asian Pac J Cancer Prev. 2012;13(4):1431-7
references: 22799344
references: J Natl Cancer Inst. 1999 Apr 7;91(7):579-81
references: 10203270
references: Annu Rev Phys Chem. 1998;49:441-80
references: 15012434
references: Nature. 1998 Jul 23;394(6691):395-9
references: 9690478
references: Protein Eng Des Sel. 2006 Aug;19(8):377-84
references: 16772308
references: Nat Rev Cancer. 2008 Dec;8(12):915-28
references: 19029956
references: Clin Cancer Res. 2007 Oct 1;13(19):5834-40
references: 17908976
references: Mol Cancer Ther. 2008 Sep;7(9):2599-608
references: 18790743
references: Biochemistry. 2001 Nov 27;40(47):14268-78
references: 11714281
references: Cancer Cell. 2004 Mar;5(3):231-9
references: 15050915
references: Endocrinol Metab Clin North Am. 2012 Jun;41(2):335-50, vi
references: 22682634
references: Nat Methods. 2007 Apr;4(4):319-21
references: 17369835
references: Cancer Res. 2003 Aug 15;63(16):5073-83
references: 12941837
references: Nat Cell Biol. 2000 Jun;2(6):313-7
references: 10854320
references: Clin Cancer Res. 2009 May 1;15(9):3058-67
references: 19383820
references: Chem Commun (Camb). 2012 Aug 7;48(61):7607-9
references: 22728887
references: Endocr Rev. 1995 Feb;16(1):3-34
references: 7758431
references: J Med Chem. 2005 Sep 8;48(18):5639-43
references: 16134929
references: Chemistry. 2003 Nov 21;9(22):5686-92
references: 14639652
references: J Phys Chem B. 2007 Dec 6;111(48):13619-25
references: 17997544